Leo Pharma consolidates global commercial organization, reducing overall unit count

In an attempt to streamline and build a more competitive organization, the Danish dermatology firm has merged a number of international commercial divisions.

Leo Pharma's head of R&D, Jörg Möller, has reduced Leo Pharma's R&D division in the past as part overall streamlining efforts, which have now also impacted the firm's commercial units | Photo: MAGNUS MØLLER

After holding meetings around the world, Leo Pharma can now announce that a number of the firm’s international sales units have been consolidated, the firm reports in a press release.

The regions dubbed Region Europe+ and Region International will be merged with the Global Therapeutic & Value Strategy team, under the new name, Global Product Strategy & International Operations, which will report to the firm’s global management.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs